EMN 2021 | The clinical application of genomics in Waldenström’s macroglobulinemia
Steven Treon
• 3 Mar 2021
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the clinical application of genomics in Waldenström’s macroglobulinemia. Dr Treon outlines the impact of MYD88 and CRCX4 mutational status on response to BTK inhibitor treatment, and gives an overview of how genomics can be utilized to optimize treatment selection for patients with Waldenström’s macroglobulinemia. This interview took place during the 2021 European Myeloma Network (EMN) congress.
Disclosures
Steven Treon, MD, PhD, has received research support from Abbvie/Pharmacyclics, Beigene, BMS and Eli Lilly; and has received consultancy fees from Janssen, Abbvie/Pharmacyclics, Beigene, BMS and X4.
